Evidence map›Paper›PMID 41364284›Full record

ArticleMolecular imaging and biology2026

PET Imaging of CD38 and IND enabling studies of [

Brian D Wright, Hailey A Houson, Solana Fernandez, Kadir Gultekin, Jonathan E McConathy, Smith Giri, Suzanne E Lapi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Brian D WrightDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Hailey A HousonDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Solana FernandezDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Kadir GultekinDepartment of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Jonathan E McConathyDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Smith GiriDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Suzanne E LapiDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. lapi@uab.edu.ORCID http://orcid.org/0000-0003-0090-0191

Funding

National Institute of Health P30CA013148Sanofi Genzyme AWD-000533137
6 · The paper itself

Abstract

backgroundCD38 is an excellent biomarker and therapeutic target for multiple myeloma due to its high expression on cancerous cells in comparison to healthy cells. PURPOSE: We aimed to adapt Isatuximab as a PET imaging agent to detect CD38 positive multiple myeloma.

methodsIn vitro studies confirmed the specificity of [

resultsUpregulation of CD38 was observed in vitro in CD38 + cells when treated with either pomalidomide or ricolinostat. In vivo evaluation of [

conclusion[

Indexed as

ADP-ribosyl Cyclase 1Antibodies, Monoclonal, HumanizedPositron-Emission TomographyPositron Emission Tomography Computed TomographyRadioisotopesZirconiumAnimalsCell Line, TumorFemaleHumansMaleMiceMice, NudeMultiple MyelomaThalidomideADP-ribosyl Cyclase 1Antibodies, Monoclonal, HumanizedisatuximabpomalidomideRadioisotopesThalidomideZirconiumZirconium-89CD38DosimetryIsatuximabZirconium-89

Identifiers

PMID41364284
PMCPMC12966236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.